Recently, one of the blog readers sent me an e-mail stating that Dr. George Cotsarelis replied to him. I then decided to resend Dr. Cotsarelis an old e-mail to which I previously got no response. My e-mail was fairly generic and I asked him about updates on various key areas of research that he might still be doing. The below is his reply from yesterday, which might just be a generic response that he sends to everyone (since the above mentioned blog reader also received a similar response):
Thank you for your interest in my research. Rest assured that we are continuing our work on hair follicle stem cells and hair follicle regeneration in the hopes of better understanding hair growth and developing treatments for hair loss.
Re PGD2R antagonists, Kythera, recently bought by Allergan, will be working on commercialization of these compounds for treatment of male pattern baldness.
Re FGF9, a small biotech company has licensed that IP and will be pursuing its commercialization.
My lab continues to work on developing novel treatments. The largest barrier is funding.
George Cotsarelis, M.D.
Note that “PGD2R antagonist” is sometimes referred to as “PGD2 antagonist”, but these two phrases are not the same thing as the “R” stands for receptor (thanks to the commenter who corrected my initial sentence).
FGF-9 is an important growth factor. If you search under the “Categories” menu (located on the upper left side if you are viewing this blog on a computer, or all the way down if you are viewing this blog on a mobile device or tablet), you will see some posts I have made in the past on various other growth factors such as FGF-2, FGF-5 and FGF-7. An interesting study on FGF-9 and wounding.
The PGD2 treatment route is far more interesting than the FGF-9 treatment route. My conclusion from reading Dr. Cotsarelis’ e-mail is that its best we focus on Allergen (Kythera)’s future announcements rather than contact Dr. Cotsarelis for any new information.